An Ottawa bioscience company is turning to the markets for an injection of capital, announcing plans this week for a bought deal offering.
Tetra Bio-Pharma, which is developing cannabinoid-based treatments for chronic pain related to cancer, is raising $10 million for working capital and general purposes as it goes through the necessary clinical trials and regulatory hurdles before its drugs can hit the market.
Echelon Wealth Partners is acting as the sole bookrunner for the offering, which will see some 18.9 million units put on the market at a price of 53 cents each. Each unit entitles a buyer to one common share of the company and one warrant for a future purchase.
OBJ360 (Sponsored)
Upgrading tech without the price tag: How one Ottawa company is changing the game
They say, “If it ain’t broke, don’t fix it.” But what if it’s outdated? Keeping up with the latest technologies can be a challenge when the pace of innovation is
How CN Cycle for CHEO powers world-class cancer research
“Kids shouldn’t have to die of cancer,” says Tamy Bell when asked why Dr. Shawn Beug’s research at CHEO is so important. Bell, after all, should know: Not only is
Shares of Tetra Bio-Pharma sat at 50 cents on the TSX Venture Exchange before markets opened Thursday.
Echelon also has an over-allotment option that could see the total funds raised rise to $1.15 million.
Tetra expects the financing to close on Feb. 13.
